Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-13
2007-11-13
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217060, C514S218000, C514S228200, C514S234500, C514S266200, C514S266400, C540S575000, C540S600000, C544S058200, C544S058600, C544S119000, C544S293000
Reexamination Certificate
active
10468788
ABSTRACT:
A compound of the formula (I)or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.
REFERENCES:
patent: 6127374 (2000-10-01), Bridges
patent: 6251912 (2001-06-01), Wissner et al.
patent: 0 837 063 (1998-04-01), None
patent: 1690856 (2006-08-01), None
patent: 05-208991 (1993-08-01), None
patent: 06-073025 (1994-03-01), None
patent: 10-152477 (1998-06-01), None
patent: 97/38983 (1997-10-01), None
Vippagunta, S.R. et. al., Crystalline Solids, Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
P. Perrotte et al., “Anti-Epidermal Growth Factor Receptor Antibody C225 Inhibits Angiogenesis in Human Transitional Cell Carcinoma Growing Orthotopically in Nude Mice”, Clinical Cancer Research, vol. 5, pp. 257-264, Feb. 1999.
D. W. Fry, “Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors”, Exp. Opin. Invest. Drugs, vol. 3, No. 6, 1994, pp. 577-595.
T. Hunter, “A thousand and one protein kinases”, Cell, vol. 50, Sep. 11, 1987, pp. 823-829.
T. Yoneda et al., “The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice”, Cancer Research, vol. 51, Aug. 15, 1991, pp. 4430-4435.
K. B. Reddy et al., “Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor”, Cancer Research, vol. 52, Jul. 1, 1992, pp. 3636-3641.
V. Brunton et al., “Cell-signaling targets for antitumour drug development”, Cancer Chemother Pharmacol., vol. 32, 1993, pp. 1-19.
W.J. Gullick et al., “Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers”, Medical Bulletin, vol. 47, No. 1, 1991, pp. 87-98.
J. Nelson et al., “Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis”, Cancer Research, vol. 55, Sep. 1, 1995, pp. 3772-3776.
D. Boschelli, “Small molecule inhibitors of receptor tyrosine kinases”, Drugs of the Future, vol. 24, No. 5, 1999, pp. 515-537.
P. Perrotte et al., “Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice”, Clinical Cancer Research, vol. 5, Feb. 199, pp. 257-264.
G. Bilder et al., “Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells”, Am. J. Physiol., 1991, vol. 260 (4-part-1), C721-C730.
L. Merkel et al., “Inhibition of EGF—Induced Vasoconstriction in Isolated Rabbit Aortic Rings with the Tyrosine Kinase Inhibitor RG50864”, Biochem. Biophys. Res. Commun., vol. 192, No. 3, May 14, 1993, pp. 1319-1326.
H. Salari et al.,“Erbstatin blocks platelet activating factor-induced protein-tyrosine phosphorylation, polyphosphoinositide hydrolysis, protein kinase C activation, seratonin secretion and aggregation of rabbit platelets”, FEBS Letters, Apr. 1990, vol. 263, No. 1, pp. 104-108.
M. Asahi et al., “Thrombin-induced human platelet aggregation is inhibited by protein-tyrosine kinase inhibitors, ST638 and genistein”, FEBS Letters, vol. 309, No. 1, Aug. 1992, pp. 10-14.
E. Munoz et al., “Tyrosine protein phosphorylation is required for protein kinase C-mediated proliferation in T cells”, FEBS Letters, vol. 279, No. 2, Feb. 1991, pp. 319-322.
A. O'Rourke et al., “Cytotoxic T-lymphocyte activation involves a cascade of signaling and adhesion events”, Nature, vol. 358, Jul. 16, 1992, pp. 253-255.
C. E. Klein et al., “Expression of a 38-kD Cell-Surface Glycoprotein in Transformed Human Keratinocyte Cell Lines”, Basal Cell Carcinomas, and Epithelial Germs, J. Invest. Dermatol., vol. 95, 1990, pp. 74-82, pp. 83-89 and 90-96.
C. Roifman et al., “Tyrosine phospharylation is an essential event in the stimulation of B lymphocytes byStephylococcus aureuscowan I”, The Journal of Immunology, vol. 146, No. 9, May 1, 1991, pp. 2965-2971.
A. Dhar et al., “Platelet-activating factor stimulation of thyrosine kinases and its relationship to phospholipase C in rabbit platelets: studies with genistein and monoclonal antibody to phosphatyrosine”, Molecular Pharmacology, vol. 37, 1990, pp. 519-525.
H. Schneider et al., “Tyrosine phosphorylation of phospholipase Cy, couples the Fε receptor mediated signal to mast cells secretion”, International Immunology, vol. 4, No. 4, 1992, pp. 447-453.
Abe Daisuke
Kawahara Eiji
Kitano Yasunori
Nakajou Masahiro
Suzuki Tsuyoshi
Mitsubishi Pharma Corporation
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3842643